Monoclonal antibodies and method for detecting dioxins and dibenzofurans

Abstract: Hybridomas are described that produce monoclonal antibodies that react with dioxins and dibenzofurans. These antibodies can be used in a sensitive immunoassay for dioxins and dibenzofurans, which permits detection of these pollutants in samples at concentrations in the range of a few parts per billion.

Description: This invention relates to monoclonal antibodies specific for toxic dioxins and dibenzofurans, hybridomas capable of secreting such antibodies and the use of the antibodies in the detection and quantitative analysis of the toxins. The U.S. Government has rights to this invention pursuant to Contract No. w-7405-ENG-48 between the U.S. Department of Energy and the University of California, for the operation of Lawrence Livermore National Laboratory. Polychlorinated dibenzodioxins (PCDD) and dibenzofurans (PCDF) are persistent, toxic pollutants which pose a threat to both human health as well as the biosphere generally. These compounds are contaminants of herbicides, such as Agent Orange, and are also generated as by-products in a variety of industrial chemical processes, as well as in the course of combustion or incineration of other polychlorinated organics, such as plastics and polychlorinated biphenyls (PCB). In view of the extensive use or occurrence of such processes, dioxins and dibenzofurans are widespread in the environment. Now that the harmful nature of these materials has become fully recognized, it has become a matter of high priority to address the issue. An important, nontrivial first step is to identify sites of pollution, which requires a simple, economical, and rapid test for detecting the presence of these compounds in samples taken from soils, human or animal tissues, as well as foodstuffs. An important aspect of a desirable test procedure relates to specificity. There are a large number of isomers both PCDD's and PCDF's, as well as PCB's, which vary in toxicity from very highly toxic to lesser toxicities, but which are also chemically similar to other, relatively harmless compounds. A second aspect of the problem is that the most toxic isomers of these compounds in the environment, i.e., 2,3,7,8-tetrachlorodibenzo-p-dioxin, is harmful in very small amounts, and is capable of being concentrated as it moves through food chains. Hence, a desirable test must be capable of detecting the presence of these harmful substances in very low concentrations. Chemical analysis of soil samples for contamination is also hampered by several other factors: (1) dioxins bind tightly to soil and show negligible solubility in water, and (2) the multiplicity of isomers and related chemical contaminants make quantitative assay by conventional gas chromatographic and mass spectrometric methods costly and time consuming. The costs and turn-around time preclude detailed sampling of an area to determine the extent of contamination, and require sophisticated centralized laboratories, unsuited for field monitoring of this health hazard. The potential advantages of immunoassay procedures over conventional analytic methods have been recognized previously, in particular, that immunoassay offers a method which is as sensitive as gas chromatography and/or mass spectrometry, while being more rapid and less expensive. One prior approach to the solution of the problem of detecting dioxins in the environment is discussed in a paper by P. w. Albro, et al, "Radioimmunoassay of Chlorinated Dibenzo-p-dioxins", Methods in Enzymology 84 : 619-639, 1982 and U. S. Patent No. 4,238,472, Albro et al, Radioimmunoassay for chlorinated Dibenzo-p-dioxins, December 9, 1980. The assay described by Albro et al is a radioimmunoassay, based on polyclonal antisera produced by immunizing rabbits with 1-amino 3,7,8,-trichlorodibenzo-p-dioxin. The Albro et al assay has not been widely applied since it has a number of limitations. It requires the frequent synthesis of ¹²⁵I-TCDD, it requires three days to complete, and it is not sufficiently specific for the 2,3,7,8-TCDD because it uses nonspecific rabbit antisera. Another approach is reported by Stephen J. Kennel et al in a paper entitled "Monoclonal Antibodies to Chlorinated Dibenzo-p-dioxins", Toxicology & Applied Pharmacology 82 , 256-263, 1986. This test for dioxins is based on monoclonal antibodies produced by immunizing BALB/c mice with a thyroglobulin conjugate of dioxin, thyroglobulin-2-adipamide, 3,7,8-trichlorodibenzo-p-dioxin. Hybridomas were produced by cell fusion of immune spleen cells and myeloma cells called SP2/0, P3, or NSI. However, the test developed by Kennel et al suffers from the disadvantage of inadequate selectivity in that their antibodies fail to react with nonprotein conjugated 2,3,7,8,-tetrachlorodibenzo-p-dioxin in solution, the most toxic of the dioxin isomers and other dioxin isomers, while reacting with compounds which are not a target for identification. Other problems are that the test utilizes a radioimmunoassay procedure with its attendant disadvantages. EP-A-242,589, published after the priority date of the present application, discloses a method of producing hybridomas capable of secreting monoclonal antibodies specific to a variety of toxic haptens, which method comprises immunisation with the unconjugated hapten. The haptens referred to include tetrachlorodibenzo dioxin. The foregoing clearly indicates that there exists a continuing need for an effective, practical test for detecting toxic dioxins. Accordingly, this invention seeks to provide monoclonal antibodies, suitable for use in an immunoassay method for dioxins, which will have the necessary selectivity and sensitivity to conclusively indicate the presence of dioxins in concentrations of a few parts per billion (nanograms per sample); which can be carried out rapidly and will be capable of being carried out in the field by a mobile facility; which will conclusively recognise the most toxic of the polychlorinated dioxins and dibenzofurans; and/or the sensitivity of which can be raised to achieve detection of toxins at the part per trillion level. The present invention provides therefore hybridomas or progeny thereof which secrete monoclonal antibodies having specific affinities for toxic isomers of polyhalogenated dibenzo-p-dioxins and dibenzofurans, including 1,3,7,8-tetrachlorodibenzo-p-dioxin, and which do not react or react marginally with hexachlorodibenzofuran, octachlorodibenzofuran, octachlorodibenzo-p-dioxin and polychlorinated biphenyls, and monoclonal antibodies having such specific affinities. In one specific embodiment the antibodies have specific affinity for toxic isomers including:- 2,3,7,8 tetrachlorodibenzo-p-dioxin, 1,3,7,8 tetrachlorodibenzo-p-dioxin, 1,2,3,7 tetrachlorodibenzo-p-dioxin, 1,2,3,8 tetrachlorodibenzo-p-dioxin, 1,2,3,7,8-pentachlorodibenzo-p-dioxin, 2,3,7,8-tetrabromodibenzo-p-dioxin, and 2,3,7,8 tetrachlorodibenzo furan. In a further embodiment the hybridomas are derived from spleenocytes of mice immunised with toxic dioxin isomer analogues, by selection according to binding affinities specific to said toxic dioxin isomer. The invention further relates in a method for detecting toxic isomers of dioxin or dibenzofuran, to the steps comprising:- a) contacting said isomers with monoclonal antibodies obtained from the hybridomas of the present invention, and b) measuring the amount of bound antibodies. The invention yet further relates to a method for producing the monoclonal antibodies of the invention, which comprises cultivating the hybridomas of the invention and harvesting the monoclonal antibodies from the cultivation product. The present invention may be used in an Enzyme-Linked-Immunosorbent-Assay ELISA procedure, whereby samples may be examined to determine the presence of polychlorinated dioxins and particularly 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), using unique monoclonal antibodies which are obtained from unique hybridoma cell lines, which will hereinafter be referred to as DD-1, DD-3, DD-4, DD-5 and DD-6. The production of the cell lines and antibodies derived therefrom will be described in greater detail below. These antibodies are characterized by high affinity and selectivity toward TCDD. Their use with the proposed ELISA test protocol permits the determination of the presence of dioxins in test samples at levels of a few parts per billion and less. Tests can be completed in hours rather than days. The use of radio-labeled compounds is obviated. with the present antibodies, tests for TCDD can be conducted in aqueous media by sonification. In a preferred mode, the sensitivity of the present test procedure can be raised by the addition of detergents in concentration on the order of .05% by volume, making it possible to detect TCDD at levels down to the order of one part per trillion. Production of the Hybridomas & Antibodies The present hybridomas DD-1, DD-3, DD-4, DD-5, and DD-6 were produced by fusion of SP2/0 mouse myeloma cells with spleenocytes obtained from immunized BALB/c and Biozzi mice. In order for animals to respond immunologically to small organic molecules, the haptens (or analogs of them) must be conjugated to carrier proteins. The first step in producing antibodies, therefore, is to synthesize an analog with a functional group that can be attached to a protein. The TCDD analog chosen for this immunization was 1-amino-3,7,8,-trichlorodibenzo-p-dioxin (A-triCDD). This compound was synthesized according to a method published by Chae et al (1977) "Synthesis of 1-amino-3,7,8-trichlorodibenzo-p-dioxin and 1-amino-2,3,7,8-tetrachlorodibenzo-p-dioxin as Haptenic Compound", Agr. Food Chem., 25 , 1207-1209. The A-triCDD can then be conjugated to carrier proteins, such as thyroglobulin, rabbit serum albumin (RSA), keyhole limpet hemocyane (KLH), and others. In our experiments, we used Bovine Serum Albumin (BSA). We then injected in BALB/c and Biozzi mice, as shown in the following table: The immunization protocol followed typically involved 10 µg injections in adjuvant per month per mouse for a period of 10 months, with a final injection a few days prior to taking the animal's spleen. After completion of the injection protocol, the spleen cells are removed and induced to grow in culture by fusing them with myeloma cells. In the present case, the spleenocytes were fused with the SP2/0 mouse myeloma cell line. These fused cells or hybridomas grow in culture and secrete monoclonal antibodies. Although each cell clone secretes only one type of antibody, from any given fusion of spleen cells typically 10,000 hybridomas are obtained. The screening procedure is therefore a matter of critical importance. In this case the hybridomas were then screened for their ability to distinguish A-triCDD-BSA and A-triCDD-RSA from BSA and RSA. On the basis of this initial screen about 25 stable, antibody-producing colonies were isolated, subcloned, and frozen. The remaining clones were again screened for their abilities to recognize free TCDD in suspension. Experimentally, on the order of 10-100 nanograms of TCDD in hexane was dried, 0.5 ml of saline with BSA (1 mg/ml) was added and sonificated for 2 hrs. Experiments with ¹⁴C-TCDD showed that about half of the TCDD became suspended in the aqueous phase, corresponding to a concentration of about 100 ppb. Identical procedures were followed for other dioxin isomers. A dilution series in microtiter plate wells was then made with the suspended TCDD, antibody added, and the competition ELISA completed. Competition ELISA test procedures are discussed in detail in the following reference: Butt, w. R. (1984) "Practical Immunoassay: The State of the Art", Marcel Dekker, Inc., N.Y., N.Y. A large part of the success that we have had in characterizing the binding specificities of our monoclonal antibodies comes from having developed a reliable competition ELISA protocol. Our preferred assay starts from stock solutions at 10 ppm in hexane of the various compounds listed in Table I. 10 µl of hexane solution is aliquoted into a small vial, evaporated under a stream of nitrogen gas, and 500 µl of a 1 mg/ml solution of BSA in phosphate buffered saline with 0.1% BSA is added. The vial is capped and placed in an ultrasonic cleaning waterbath for two hours. Two hours of sonification gives a more reproducible assay than does an hour. During the sonification, the hexane appears to evaporate completely, and one is left with an aqueous solution containing the dioxin. Microtiter plates coated with A-triCDD-RSA are blocked with a three percent solution of ovalbumin and a two-fold dilution series of sonificated dioxin-BSA is then made, covering the range 100 ppb-0.1 ppb. In each well of the plate 100 µl of the sonificated dioxin-BSA solution is mixed with an equal volume of antibody. The antibody partitions between the dioxin adsorbed to the BSA, and the A-tri-CDD-RSA on the plate. Figure 1 shows the results of a competition ELISA using monoclonal antibody DD-1, which is representative of our detailed procedure with other antibodies as well. A-TriCDD-RSA was adsorbed onto the surface of the wells of a microtiter plate. The various competitors listed were suspended in saline containing bovine serum albumin (BSA). These solutions were made by sonificating 10 µl of dioxin solution in hexane with 500 µl of saline-BSA. A dilution series of these dioxin-BSA solutions was then made covering the range of 100-0.2 ppb, and placed in the microtiter plate wells. An equal volume of DD-1 monoclonal antibody was then added, and allowed to react for 1 hour. The antibody binds either to the A-TriCDD-RSA on the plate or the dioxin in solution. After the hour, the solution phase is removed, the plate washed, and it is reincubated for an hour with peroxidase-conjugated goat-anti-mouse-immunoglobulins. A second washing is then done, and substrate (ABTS) added to the peroxidase. The enzyme-antibody conjugate and substrate function as a "developer", allowing the visualization of the DD-1 bound to the A-triCDD-RSA on the plate. Results are then expressed as a fraction of the response in wells with no competitor. In this example, DD-1 does not react with octachlorodibenzodioxin. At about 20 ppb of 2,3,7,8-TCDD the relative ELISA response is half of control, meaning that half the DD-1 antibody bound to the solution phase dioxin and half bound to the A-triCDD-RSA on the plate. For 1,2,3,7(8)-TCDD, 50% inhibition occurs at about 4ppb, indicating the DD-1 prefers 1,2,3,7(8)-TCDD to 2,3,7,8-TCDD. Based on this test, five hybridomas (named DD-1, DD-3, DD-4, DD-5 and DD-6) were selected for further study. Table II shows the specificity of these antibodies using this assay for a variety of dioxins, dibenzofuran, PCBs and other chlorinated hydrocarbons. The above Graph and Table II show representative competition data using several chlorinated compounds as competitors. For such data, one can determine the concentration required to inhibit antibody binding by 50% (I₅₀). Table II lists the I₅₀ for all compounds tested with the antibodies. In reporting these values, factors of two are about the limit of significance. All six antibodies have highest affinity for tetrachlorodibenzodioxins, with highest affinity for the mixed 1,3,7,8, isomer. They have slightly less affinity for the 2,3,7,8-TCDD and 2,3,7,8-TCDBF. DD-4 has some reactivity with the 1,2,3,6,7,8-hexa-CDD. Up to the highest concentration tested (100 ppb) all antibodies either do not react or react only marginally with hexachloro-DBF, octochloro-DBF, octachloro-DD, and PCB's. The binding specificities of these antibodies are highly desirable, since they prefer the most toxic of the dioxin and dibenzofuran isomers. It is our experience that different mice will produce clones with different binding specificity and affinity. Each mouse appears nearly unique in the way it responds to an immunogen. Multiple clones from the same mouse are often quite similar. As such, we were interested in deriving a set of monoclonal antibodies from different mice. We have selected five hybridomas, from different mice using the same basic protocol. All recognize 2,3,7,8-TCDD. These assays are highly reproducible, with replicate assays on TCDD the I₅₀ value varied less than 20%. SAMPLE ANALYSIS The test procedures for determining the presence of dioxins and dibenzofurans is in principle again a competition ELISA test using the antibodies described in the specification above. The samples may be soil samples, tissue samples, or food samples. These samples are initially pretreated in order to extract the dioxins or dibenzofurans and quantitatively transfer them into a medium suitable for use in the immunoassay scheme. Soil samples, for example, are treated according to the following protocol. Initially, the dioxins or dibenzofurans are extracted into a hexane in accordance with the standard EPA method 613. At this point, the extract is put through one or more clean-up steps to remove interfering substances, as discussed in greater detail below. Thereafter, the sample is concentrated near dryness. At this juncture, the sample residue is resuspended in saline solution. It has been found that reproducible and reliable results are obtained by sonification of the saline solution for about 2 hours, leading to satisfactory determinations capable of identifying the presence of toxins in the part per billion range. The sensitivity can be drammatically improved by the addition of controlled quantities of detergent. Our preferred detergents are Cutscum™ and Tween-20. We have found that, by reducing the concentration of these detergents to about .05% by volume, it is possible to remarkably improve the sensitivity of the assay to detect dioxins or dibenzofurans at concentrations as low as a few parts per trillion. The remainder of the procedure is carried out by placing the sample on the microtiter plate, adding the antibody, proceeding with the competition ELISA assay, collecting and analyzing the data by microcomputer. The procedure is further illustrated by the following examples. Example I 10 grams of wet soil is weighed into a 500 ml amber bottle and is thoroughly mixed with 20 grams of sodium sulfate. 20 ml of methanol and 150 ml of hexane are added and the mixture is shaken for at least 3 hours. The hexane layer is decanted from the mixture, filtered and the volume reduced to 1 ml on a rotary evaporator. The residue is applied to a short, disposable chromatography column (silica or alumina, 1 gram) and eluted with either hexane or 20% methylene chloride/hexane, respectively. The solvent is then removed by a stream of dry nitrogen gas and the residue is suitable for incorporation into the immunoassay scheme. The purpose of the chromatography column is to remove any extraneous material in the soil which may interfere with the assay. Soils may contain a large amount of hexane soluble, organic material in which the dioxin may partition in preference to the solvent used in the immunoassay rendering the dioxin inaccessible to the antibodies. Without the chromatography, the immunoassay will not work with some soil types. The above two conditions both work equally well and others should as well. This procedure should work equally well on tissue and food samples. Example II The soil extract or test compound dissolved in hexane is dryed and 5 microliters of a 5% (v/v) solution of detergent in methanol (e.g., Cutscum™) is added. The methanol is then evaporated by a stream of N₂. 500 microliters of Phosphate Buffered Saline [0.01 M phosphate, 0.1 M NaCl, pH 7.2] (PBS-7) is then added and the reaction vial tightly capped. The vial is then placed in a Bransonic 220 ultrasonic cleaner and sonificated for 30 minutes. This material is then titered for dioxin content in a competition ELISA. The foregoing description of a preferred embodiment of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed, and obviously many modifications and variations are possible in light of the above teaching. The embodiment was chosen and described in order to best explain the principles of the invention and its practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto.

Claims: Hybridomas or progeny thereof which secrete monoclonal antibodies having specific affinities for toxic isomers of polyhalogenated dibenzo-p-dioxins and dibenzofurans, including 1,3,7,8-tetrachlorodibenzo-p-dioxin, and which do not react or react marginally with hexachlorodibenzofuran, octachlorodibenzofuran, octachlorodibenzo-p-dioxin and polychlorinated biphenyls. Hybridomas according to claim 1 which secrete antibodies which do not react or react marginally with 1,2,3,6,7,8 hexachlorodibenzo-p-dioxin. Hybridomas according to claim 1 or 2 which secrete antibodies specific to further toxic tetrachlorodibenzo-p-dioxin isomers. Hybridomas according to any one of the preceding claims, further defined in that said toxic isomers include: 2,3,7,8 tetrachlorodibenzo-p-dioxin, 1,2,3,7 tetrachlorodibenzo-p-dioxin, 1,2,3,8 tetrachlorodibenzo-p-dioxin, 1,2,3,7,8-pentachlorodibenzo-p-dioxin, 2,3,7,8-tetrabromodibenzo-p-dioxin, and 2,3,7,8 tetrachlorodibenzo furan. The hybridomas according to any one of the preceding claims which are derived from spleenocytes of mice immunised with toxic dioxin isomer analogues, by selection according to binding affinities specific to said toxic dioxin isomer. Monoclonal antibodies having specific affinities for toxic isomers of polyhalogenated dibenzo-p-dioxins and dibenzofurans, including 1,3,7,8-tetrachlorodibenzo-p-dioxin, and which do not react or react marginally with hexachlorodibenzofuran, octachlorodibenzofuran, octachlorodibenzo-p-dioxin and polychlorinated biphenyls. Monoclonal antibodies according to claim 6 which do not react or react marginally with 1,2,3,6,7,8 hexachlorodibenzo-p-dioxin. Monoclonal antibodies according to claim 6 or 7 specific to further toxic tetrachlorodibenzo-p-dioxin isomers. Monoclonal antibodies according to any one of claims 6 to 8 further defined in that said toxic isomers include: 2,3,7,8 tetrachlorodibenzo-p-dioxin, 1,2,3,7 tetrachlorodibenzo-p-dioxin, 1,2,3,8 tetrachlorodibenzo-p-dioxin, 1,2,3,7,8-pentachlorodibenzo-p-dioxin, 2,3,7,8-tetrabromodibenzo-p-dioxin, and 2,3,7,8 tetrachlorodibenzo furan. Monoclonal antibodies according to any one of claims 6 to 9, further defined in that they are characterised by affinities approximately as given in Table II. In a method for detecting toxic isomers of dioxin or dibenzofuran, the steps comprising: a) contacting said isomers with monoclonal antibodies obtained from hybridomas of any one of claims 1 to 5, and b) measuring the amount of bound antibodies. A method according to claim 11 wherein said isomers are extracted from a sample, and resuspended in saline solution which comprises detergent by sonification. A method according to claim 11 or 12 wherein said bound antibodies are measured using competition ELISA test procedures. A method for producing monoclonal antibodies as defined in any one of claims 6 to 10 which comprises cultivating hybridomas as defined in any one of claims 1 to 5 and harvesting the monoclonal antibodies from the cultivation product.

Inventors: STANKER LARRY H, VANDERLAAN MARTIN, WATKINS BRUCE E, STANKER, LARRY H., VANDERLAAN, MARTIN, WATKINS, BRUCE E.
Applicants: UNIV CALIFORNIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Application year: 1987
Main classification: C12N5
IPC codes: C12P21, G01N33, C07K16, C12N5, C12N15, C07K14, C12R1